statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Mahesh Krishnan Elected to Halozyme's Board of Directors Mahesh Krishnan Elected to Halozyme's Board of Directors PR Newswire SAN DIEGO, April 25, 2024 SAN DIEGO, April 25, 2024 /PRNewswire...

Mahesh Krishnan Elected to Halozyme's Board of Directors

Latest Ratings for HALO
 DateFirmActionFromTo Nov 2021Wells FargoMaintainsOverweight Nov 2021JMP SecuritiesMaintainsMarket Outperform Nov 2021SVB LeerinkMaintainsOutperform
 View More Analyst...

9 Analysts Have This To Say About Halozyme Therapeutics

It has been about a month since the last earnings report for Mirum Pharmaceuticals, Inc. (MIRM). Shares have lost about 12.5% in that time frame, underperforming the S&P 500.Will the recent negative...

Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound?

A month has gone by since the last earnings report for Denali Therapeutics Inc. (DNLI). Shares have added about 2.8% in that time frame, underperforming the S&P 500.Will the recent positive trend...

Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?

Investors in Halozyme Therapeutics Inc (HALO) saw new options begin trading this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the HALO...

First Week of May 17th Options Trading For Halozyme Therapeutics (HALO)

Halozyme Therapeutics, Inc. (NASDAQ:HALO  Free Report)  Equities researchers at Zacks Research lifted their Q1 2025 EPS estimates for Halozyme Therapeutics in a research report issued...

Zacks Research Analysts Raise Earnings Estimates for Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Halozyme Therapeutics, Inc. (NASDAQ:HALO  Get Free Report) SVP Michael J. Labarre sold 10,000 shares of the companys stock in a transaction on Tuesday, March 12th. The stock was sold at...

Michael J. Labarre Sells 10,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock

Tealwood Asset Management Inc. lessened its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO  Free Report) by 2.6% in the fourth quarter, according to the company in its most...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Tealwood Asset Management Inc.

Townsquare Capital LLC raised its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO  Free Report) by 21.9% during the 3rd quarter, according to the company in its most recent 13F...

Townsquare Capital LLC Raises Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Envestnet Asset Management Inc. raised its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO  Free Report) by 15.7% in the 3rd quarter, according to its most recent 13F filing with the...

Envestnet Asset Management Inc. Raises Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Volume	526,388.00
52-Wk High	$45.00
52-Wk Low	$29.85

HALO Halozyme Therapeutics Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals